Skip to main content
TEVA logo

TEVA · Teva Pharmaceutical Industries Ltd · Webcasts, Transcripts & Audio

Track TEVA — free
$42.62 +0.05 (+0.12%) At close · Nov 17 Play latest call Q3 2026 earnings call transcript
Market Cap
$49.73B
Shares
1.17B
Volume · Nov 17 7.02M Avg daily vol (3M) 6.16M

Teva Pharmaceutical Industries Ltd Webcasts

Earnings calls, investor updates, investor days and conferences for Teva Pharmaceutical Industries Ltd (TEVA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-03
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Transcript
Confident tone Access, litigation and program risks Biopharma transformation and margins Neuroscience launches and pipeline
Revenue
$4.39B
▼ 1.9% YoY
Diluted EPS
$0.20
▼ 45.9% YoY
Gross margin
55.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-10-09
Teva Pharmaceutical Industries Ltd (TEVA) October 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-23
Teva Pharmaceutical Industries Ltd (TEVA) September 23, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-22
Teva Pharmaceutical Industries Ltd (TEVA) September 22, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-22
Teva Pharmaceutical Industries Ltd (TEVA) September 22, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-14
Teva Pharmaceutical Industries Ltd (TEVA) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-29
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Transcript
Confident tone Pipeline launches (olanzapine, Ecopipam) and milestones Innovative portfolio growth (Austedo, Ajovy, Uzedy) 2026 guidance raise
Revenue
$4.14B
▼ 0.8% YoY
Diluted EPS
$-0.49
▼ 304.2% YoY
Gross margin
52.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Teva Pharmaceutical Industries Ltd (TEVA) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-12
Teva Pharmaceutical Industries Ltd (TEVA) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-29
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2026 Earnings Call Transcript
Confident tone R&D Pipeline and Readouts Organizational Effectiveness and Cost Savings Pivot to Growth Strategy
Revenue
$3.98B
▲ 2.3% YoY
Diluted EPS
$0.31
▲ 72.2% YoY
Gross margin
49.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-10
Teva Pharmaceutical Industries Ltd (TEVA) March 10, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-01-28
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2025 Earnings Call Transcript
Confident tone Business development and capital allocation Innovative portfolio growth Generics business stability
Revenue
$1.50B
▼ 64.5% YoY
Gross margin
177.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-01-13
Teva Pharmaceutical Industries Ltd (TEVA) January 13, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-11-05
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2025 Earnings Call Transcript
Confident tone AUSTEDO CMS price negotiation and 2027 targets Cost savings program and operational efficiency Long-acting injectable (LAI) schizophrenia franchise
Revenue
$4.48B
▲ 3.4% YoY
Diluted EPS
$0.37
Gross margin
51.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2025 Earnings Call Transcript
Confident tone Generics business performance Biosimilars R&D pipeline and innovation
Revenue
$4.18B
▲ 0.3% YoY
Diluted EPS
$0.24
Gross margin
50.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2025 Earnings Call Transcript
Confident tone Innovative brands growth Long-acting injectable franchise in schizophrenia 2027 strategic targets and Pivot to Growth
Revenue
$3.89B
▲ 1.9% YoY
Diluted EPS
$0.18
Gross margin
48.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2025-02-24
Teva Pharmaceutical Industries Ltd (TEVA) February 24, 2025 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY24 · Q4
2025-01-29
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Transcript
Confident tone Financial performance and guidance Generics and biosimilars 2027 margin targets and operational leverage
Revenue
$4.23B*
▼ 5.1% YoY
Gross margin
50.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Transcript
Confident tone Innovative portfolio growth (AUSTEDO, AJOVY, UZEDY) TAPI divestment Generics business
Revenue
$4.33B
▲ 12.5% YoY
Diluted EPS
$-0.39
▼ 750% YoY
Gross margin
49.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2024 Earnings Call Transcript
Confident tone R&D pipeline progress (Olanzapine, TL1A, ICS/SABA, MSA) AUSTEDO performance and IRA considerations Innovative portfolio: AJOVY, UZEDY, SIMLANDI
Revenue
$4.16B
▲ 7.4% YoY
Diluted EPS
$-0.75
Gross margin
48.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2024 Earnings Call Transcript
Confident tone Biosimilars Launches and Outlook AUSTEDO Growth and Guidance Olanzapine LAI Phase III Results
Revenue
$3.82B
▲ 4.3% YoY
Diluted EPS
$-0.12
Gross margin
46.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-31
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2023 Earnings Call Transcript
Confident tone Innovative brands: Austedo and Ajovy New product launches (Uzedy, biosimilars) Pivot to Growth strategy execution and 2023 results
Revenue
$4.46B*
▲ 14.8% YoY
Gross margin
54.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2023 Earnings Call
Revenue
$3.85B
▲ 7.1% YoY
Diluted EPS
$0.06
▲ 20% YoY
Gross margin
48.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2023 Earnings Call
Revenue
$3.88B
▲ 2.4% YoY
Diluted EPS
$-0.78
Gross margin
46.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2023 Earnings Call
Revenue
$3.66B
▲ 0% YoY
Diluted EPS
$-0.20
Gross margin
43.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-08
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2022 Earnings Call
Revenue
$3.88B*
▼ 5.3% YoY
Diluted EPS
$-1.17
Gross margin
45.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2022 Earnings Call
Revenue
$3.60B
▼ 7.5% YoY
Diluted EPS
$0.05
▼ 80.8% YoY
Gross margin
46.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-07-27
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2022 Earnings Call
Revenue
$3.79B
▼ 3.2% YoY
Diluted EPS
$-0.23
▼ 221.1% YoY
Gross margin
47.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2022 Earnings Call
Revenue
$3.66B
▼ 8.1% YoY
Diluted EPS
$-0.86
▼ 1328.6% YoY
Gross margin
47.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-09
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2021 Earnings Call
Revenue
$4.10B*
▼ 8% YoY
Gross margin
50.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-27
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2021 Earnings Call
Revenue
$3.89B
▼ 2.3% YoY
Diluted EPS
$0.26
Gross margin
46.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-28
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2021 Earnings Call
Revenue
$3.91B
▲ 1% YoY
Diluted EPS
$0.19
▲ 46.2% YoY
Gross margin
47.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2021 Earnings Call
Revenue
$3.98B
▼ 8.6% YoY
Diluted EPS
$0.07
▲ 16.7% YoY
Gross margin
47.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-10
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2020 Earnings Call
Revenue
$4.45B
▼ 0.3% YoY
Diluted EPS
$0.14
▲ 40% YoY
Gross margin
46.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2020 Earnings Call
Revenue
$3.98B
▼ 2.8% YoY
Diluted EPS
$-3.97
Gross margin
46.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2020 Earnings Call
Revenue
$3.87B
▼ 7.3% YoY
Diluted EPS
$0.13
Gross margin
45.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2020 Earnings Call
Revenue
$4.36B
▲ 5% YoY
Diluted EPS
$0.06
Gross margin
47.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-12
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2019 Earnings Call
Revenue
$4.47B
▲ 1.1% YoY
Diluted EPS
$0.10
Gross margin
43.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–38 of 38 webcasts
Key facts CIK 818686 CUSIP M8769Q102 13F (30d) 628 filings 563 filers Visit website Investor relations